Clinical Trials Logo

Positive Hormonal Receptors clinical trials

View clinical trials related to Positive Hormonal Receptors.

Filter by:
  • None
  • Page 1

NCT ID: NCT03636776 Terminated - Clinical trials for Metastatic Breast Cancer

Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer

EPOCA
Start date: December 29, 2016
Phase: N/A
Study type: Interventional

Metastatic breast cancer (MBC) is a dark prognostic disease with survival at 5 years of less than 20% and a median survival of 24 to 30 months after diagnosis of metastasis. Thus, metastatic diagnosis can be expected to have a different impact on the quality of life of patients in early and advanced stages. However, MBC benefits from therapeutics that improve patients' quality of life and even improve overall survival. The main objectives of this prospective study are : - to evaluate the evolution over time of the quality of life of patients treated for positive hormonal receptors (RH+) metastatic breast cancer, according to the therapeutic class ; - to evaluate the psychological vulnerability of these patients since the announcement of their metastatic diagnosis and during their treatments. Finally, when interviewing oncologists, to know the factors involved in a treatment change decision process for the same patient.